SCHEMBL323083

SCHEMBL323083

O=C(OCc1cccc(Cl)c1Cl)N1C=Cc2ccccc2C1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.38
HSD17B3 P37058 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
MMP1 P03956 1/20 0.34
MMP2 P08253 1/20 0.34
MMP9 P14780 1/20 0.34
MMP12 P39900 1/20 0.34
HDAC3 O15379 1/20 0.34
ALDH1A1 P00352 2/20 0.34
ENPP2 Q13822 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
POLB P06746 1/20 0.33
NPC1 O15118 1/20 0.33
NR4A2 P43354 1/20 0.33
RAB9A P51151 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
TAAR1 Q96RJ0 1/20 0.33
MAPT P10636 1/20 0.32
CASP3 P42574 1/20 0.32
SENP8 Q96LD8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL324263 0.92 L3MBTL1 (0.40) HSD17B3MMP1MMP2MMP9MMP12
SCHEMBL324646 0.87 HSD17B3 (0.38) HSD17B3HDAC3ALDH1A1TDP1MAPT
SCHEMBL323574 0.83 GRIN2B (0.41) MMP1MMP2MMP9MMP12ALDH1A1
SCHEMBL325232 0.83 HSD17B3 (0.46) HSD17B3PTGDR2HDAC3
SCHEMBL324065 0.83 KMT2A (0.44) ALDH1A1TDP1L3MBTL1MAPT
SCHEMBL323930 0.83 HSD17B3 (0.46) HSD17B3HDAC3ENPP2TDP1NR4A2
SCHEMBL324997 0.82 F13A1 (0.39) PTGDR2MMP1MMP2MMP9MMP12
SCHEMBL324431 0.82 ALDH1A1 (0.37) HSD17B3HDAC3ALDH1A1POLBTAAR1
SCHEMBL324798 0.82 GRIN2B (0.40) HSD17B3HDAC3ALDH1A1POLBNPC1
SCHEMBL322852 0.82 MMP1 (0.39) IDO1HSD17B3PTGDR2MMP1MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590944-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS Actelion Pharmaceuticals Ltd. (CH) 2013-05-15 EP disclosed
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD. (CH) 2013-05-02 US disclosed
WO-2012004722-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109685-A1 1-PHENYL-SUBSTITUTED HETEROCYCLYL DERIVATIVES AND THEIR USE AS PROSTAGLANDIN D2 RECEPTOR MODULATORS PTGER1, PTGDR, PTGDR2 IDO1 910/4885HSD17B3 967/4885PTGDR2 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.